1. A compound of the formula

10

wherein A is the group H or $-(CH_2)_5$

- The compound of claim 1, (2S,3S,5S,7Z,10Z)-5-[(S)-2-15 formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.
- The compound of claim 1, (2S,3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid
 lactone.

4. A pharmaceutical composition comprising

a) about 5% to about 95% of a compound of 25 formula

30

35

wherein A is the group H or -(CH₂)₅-; and

- b) 5% to 95% of a pharmaceutically acceptable carrier material, said composition being formulated in a unit dosage form.
- The composition of claim 4 wherein said composition is formulated in an oral unit dosage form.
 - The composition of claim 5 wherein said oral unit dosage form is a tablet, dragee, capsule, solution, emulsion or suspension.
- The composition of claim 4 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.
- 8. The composition of claim 4 wherein compound I is (2s, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.
- A method of treating obesity in an afflicted mammal comprising administering to the mammal a compound of the formula

30 Wherein A is the grou

10

25

wherein A is the group
$$H$$
 or $-(CH_2)_5$

in an amount which is effective in treating obesity.

35 10. The method of claim 9 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

- 11. The method of claim 9 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.
- 12. The method of claim 9 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.
- 13. A method of treating hyperlipaemia in an afflicted mammal comprising administering to the mammal a compound of the formula

• • •

wherein A is the group
$$H_{\text{or -(CH}_2)_5^-}$$
,

in an amount which is effective in treating

20 hyperlipaemia.

15

25

- 14. The method of claim 13 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy)-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.
- 15. The method of claim 13 wherein compound I is (2s, 3s,5s)-5-[(s)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.
- 30 16. The method of claim 13 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

17. A method of preventing obesity in a mammal comprising administering to the mammal a compound of the formula

wherein A is the group or -(CH₂)₅-,

5

25

30

H N. V.

in an amount which is effective in preventing obesity.

- 18. The method of claim 17 wherein compound I is (25, 15 35.55.72.102)-5-[(5)-2-Formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7.10-hexadecadienoic acid lactone.
 - 19. The method of claim 17 wherein compound I is (28,38,58)-5-[(8)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.
- 20. The method of claim 17 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg 20 body weight of the mammal.
 - 21. A commercially-produced foodstuff comprising a compound of the formula

wherein A is the group H or $-(\mathrm{CH_2})_5$, admixed with a material suitable for consumption.

35 22. The foodstuff of claim 20 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7.10-hexadecadienoic acid lactone.

23. The foodstuff of claim 20 wherein compound I is (25, 35,55)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

C